(Efalizumab)Biosimilar Reference Antibody-GS40209 新品

货号：GS40209

Efalizumab (marketed under the brand name Raptiva®) was a humanized monoclonal IgG1 antibody developed as a targeted biologic therapy for moderate to severe chronic plaque psoriasis. It functioned as a T-cell modulator by specifically binding to the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1). This binding inhibited the interaction between LFA-1 on T cells and intercellular adhesion molecule-1 (ICAM-1) on antigen-presenting cells and vascular endothelium. By blocking this critical costimulatory signal and preventing T-cell adhesion and trafficking into the skin, efalizumab effectively reduced the pathogenic T-cell activation and migration that drive psoriatic plaque formation and inflammation.